Tivic Health Systems ( (TIVC) ) has shared an announcement.
On February 18, 2025, Tivic Health Systems announced the appointment of Michael Handley as Chief Operating Officer and President of its Tivic Biopharma division. Handley, a seasoned professional with extensive experience in drug and device commercialization, will lead Tivic’s efforts to advance its newly licensed product, Entolimod, through regulatory approval and commercialization. This strategic move aims to expand Tivic’s biopharmaceutical capabilities and enhance its therapeutics pipeline, potentially increasing shareholder value.
More about Tivic Health Systems
Tivic Health Systems, Inc. is a diversified therapeutics company focusing on harnessing the immune and autonomic nervous systems to combat disease and restore health. The company employs a multi-pronged approach, combining bioelectronic and biologic medicines to address disorders and diseases through neural and molecular pathways. Tivic Health’s first FDA-approved product, ClearUP, is designed to treat sinus pain and pressure and is available through online retailers and commercial distributors.
YTD Price Performance: 33.82%
Average Trading Volume: 12,403,093
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.35M
See more insights into TIVC stock on TipRanks’ Stock Analysis page.